Apixaban News and Research

RSS
New research focusing on VTE presented at ASH Annual Meeting

New research focusing on VTE presented at ASH Annual Meeting

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Emerging blood thinners to prevent stroke

Emerging blood thinners to prevent stroke

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Venous thromboembolism drugs to experience robust growth by 2019

Venous thromboembolism drugs to experience robust growth by 2019

Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin

Phase 3 AVERROES trial reveals apixaban effective for atrial fibrillation patients unsuitable for warfarin

Data monitoring committee recommends early termination following impressive results of AVERROES study

Data monitoring committee recommends early termination following impressive results of AVERROES study

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

New oral blood-thinning drugs may have dangerous interactions when taken with prescription drugs : Study

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

Novel oral anticoagulants to drive venous thromboembolism drug market to $5 billion in 2018

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients

Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients

Application for regulatory approval of apixaban in Europe to be submitted

Application for regulatory approval of apixaban in Europe to be submitted

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Pfizer announces fiscal 2009 third-quarter results

Pfizer announces fiscal 2009 third-quarter results

New type of anti-clotting drug called Apixaban

New type of anti-clotting drug called Apixaban

Factor Xa inhibitor Apixaban and antiplatelet therapy after acute coronary syndrome

Factor Xa inhibitor Apixaban and antiplatelet therapy after acute coronary syndrome